Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q3 2025 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, Nov 7, 2025
Slide 1: Q3 FY 2025
(6) SANUWAVE Wound Care Technologies Q3 FY 2025 November 7, 2025
Slide 2: Live Presentation Participant Dial-in Information
Live Presentation Friday, November 7, 2025, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-274-8461 Toll/International: 1-203-518-9814 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1741017&tp_key=73ef3
Slide 3: Forward Looking Statements and Non-GAAP Financial Measures
3 Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectati
Slide 4: Financials Q3 2025
4 Financials Q3 2025 Consistent topline growth while managing operating costs. (in millions) Q3 2025 Q3 2024 YoY Revenue $11.5 $9.4 + 22% Gross Profit $8.9 $7.1 + 25% Gross Margin 77.9% 75.5% +244 bp Operating Expense $7.5* $5.1 +47% Revenue Gross Profit Operating Income Operating Income $1.5* $2.0
Slide 5: Improved operational results
5 Improved operational results See Non-GAAP Financial Measures disclosure included on slide 3
Slide 6: Growing UltraMist Systems & Consumables Sales
6 Growing UltraMist Systems & Consumables Sales Growth in UltraMIST systems and Applicators both sequentially year on year. Record quarter for both. $8.0 + 27% yoy • 1,416 systems in the field at $7.0 + 6% seq end of Q3 2025 $6.0 +20% yoy • In Q3 2025: 155 systems sold $5.0 +27% seq (vs 124 in Q3 20
Slide 7: Q4 and FY 2025 Revenue Guidance
7 Q4 and FY 2025 Revenue Guidance Q4 2025 FY 2025 REVENUE REVENUE TARGET $13-14 $44-45 million Million (+35-39%) vs vs Q4 2024 REVENUE FY 2024 REVENUE of $10.3 million of $32.6 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for patients, payors, and providers. SANUWAVE is in a prime position to benefit: ▪ Approved products protected by strong IP ▪ Strong existing reimbursement with room to impr